>
Switch to:

Cellectar Biosciences Tax Expense

: $0.00 Mil (TTM As of Sep. 2021)
View and export this data going back to 2005. Start your Free Trial

Cellectar Biosciences's tax expense for the months ended in Sep. 2021 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2021 was $0.00 Mil.


Cellectar Biosciences Tax Expense Historical Data

The historical data trend for Cellectar Biosciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Tax Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cellectar Biosciences Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Tax Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cellectar Biosciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectar Biosciences  (NAS:CLRB) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Cellectar Biosciences Tax Expense Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences Business Description

Cellectar Biosciences logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.
Executives
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE COLT NECK NJ 07722
Swirsky Douglas J director C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD SUITE 455 ROCKVILLE MD 20850
Neis John director 505 S. ROSA ROAD, SUITE 201 MADISON WI 53719
Hill Stephen A director 50 AVENUE GENERAL DE GAULLE BRUXELLES C9 9999999999
Driscoll Frederick W director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DRISCOLL FREDERICK W a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Loren Stefan director 3226 AVENIDA DE SUENO CARLSBAD CA 92009
Elefant Dov officer: Chief Financial Officer EPICEPT CORPORATION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS NJ 07632
Caruso James V director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC. 8383 GREENWAY BLVD STE 600 MIDDLETON WI 53562
Longcor Jarrod officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC. 300 GEORGE STREET, SUITE 301 NEW HAVEN CT 06511
Grachev Igor D officer: Chief Medical Officer 15 REID LANE MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD MALVERN PA 19355
Posner Brian M officer: Chief Financial Officer 1590 REED ROAD PENNINGTON NJ 08534
Hamill John P. officer: Interim CFO 4092 NEW HOPE ROAD FURLONG PA 18925
Kolean Chad J officer: VP, Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON WI 53716
Hertzberg Richard other: significant owner 1329 STRATFORD COURT DEL MAR CA 92014

Cellectar Biosciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)